

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **March 28, 2007**

AngioDynamics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	000-50761	11-3146460
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
603 Queensbury Avenue, Queensbury, New York		12804
(Address of Principal Executive Offices)		(Zip Code)
	(518) 798-1215	
	(Registrant's telephone number, including area code)	

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 – Other Events.

On March 28, 2007, the jury in the previously disclosed lawsuit filed on January 6, 2004 by Diomed, Inc. (“Diomed”) against AngioDynamics, Inc. (the “Company”) entitled Diomed, Inc. v. AngioDynamics, Inc., civil action no. 04 10019 RGS in the U.S. District Court for the District of Massachusetts, returned a verdict in favor of Diomed. Diomed’s complaint alleged that the Company infringed on Diomed’s U.S. patent no. 6,398,777 by selling a kit for the treatment of varicose veins (now called the “VenaCure Procedure Kit”) and two diode laser systems: the Precision 980 Laser and the Precision 810 Laser, and by conducting a training program for physicians in the use of the Company’s VenaCure Procedure Kit. The Company intends to set aside or appeal the verdict.

A copy of the press release issued by the Company on March 28, 2007, announcing its intention to set aside or appeal the verdict is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 – Financial Statements and Exhibits.

(d) Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated March 28, 2007.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANGIODYNAMICS, INC.
(Registrant)

Date: March 30, 2007

By: /s/ Joseph G. Gerardi
Joseph G. Gerardi
Vice President, Chief Financial Officer
and Treasurer

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated March 28, 2007.

Company Contact:

AngioDynamics, Inc.
 Joe Gerardi
 (800) 772-6446 x1115
 jgerardi@AngioDynamics.com

Investor Relations Contacts:

EVC Group, Inc.
 Jennifer Beugelmans/Doug Sherk
 (646) 201-5447
 jbeugelmans@evcgroup.com
 dsherk@evcgroup.com

Media Contact:

EVC Group, Inc.
 Steve DiMattia
 (646) 201-5445
 sdimattia@evcgroup.com

ANGIODYNAMICS TO APPEAL PATENT INFRINGEMENT VERDICT

QUEENSBURY, N.Y. March 28, 2007—AngioDynamics, Inc. (NASDAQ: ANGO), announced it will act to set aside, and if necessary, will appeal the jury verdict returned in favor of Diomed, Inc. in a trial for patent infringement brought in the Federal District Court in Boston, Massachusetts. The jury found infringement was not willful.

Today's jury verdict arises from a lawsuit filed by Diomed in January 2004, asserting infringement of U.S. patent No. 6,398,777 by AngioDynamics' VenaCure(R) product line, a laser system used for the treatment of severe varicose veins. In conjunction with the verdict, Diomed was awarded compensatory monetary damages in the amount of \$8.36 million.

"AngioDynamics strongly disagrees with the verdict reached by the jury today and we will immediately ask the court to overturn it and, if necessary, appeal the decision," said Eamonn P. Hobbs, AngioDynamics' chief executive officer. "We firmly believe our VenaCure procedure falls outside the scope of the Diomed patent, and are confident this will be established through the court's review of the verdict or the appeal process."

AngioDynamics will be filing its motion to overturn the verdict within 10 days, and, if denied, an appeal will be promptly filed in the U.S. Court of Appeals for the Federal Circuit in Washington, D.C.

AngioDynamics noted that, regardless of the final outcome of the lawsuit, the Company anticipates that it will be fully indemnified pursuant to the terms of the Company's supply and distribution agreement with its laser system sub-supplier.

About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.angiodynamics.com.

Safe Harbor

The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended June 3, 2006, may affect the actual results achieved by the Company.